The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 23, 2018

Filed:

Feb. 10, 2015
Applicant:

Abt Molecular Imaging, Inc., Lousiville, TN (US);

Inventors:

Aaron McFarland, Knoxville, TN (US);

Atilio Anzellotti, Knoxville, TN (US);

Daniel Hillesheim, Knoxville, TN (US);

Clive Brown-Proctor, Knoxville, TN (US);

Mark Haig Khachaturian, Knoxville, TX (US);

Andrew Land, Knoxville, TN (US);

Assignee:

ABT Molecular Imaging, Inc., Louisville, TN (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 51/00 (2006.01); A61M 36/14 (2006.01); G21K 5/02 (2006.01); B01J 19/00 (2006.01); A61K 51/04 (2006.01); A61K 51/02 (2006.01);
U.S. Cl.
CPC ...
G21K 5/02 (2013.01); A61K 51/025 (2013.01); A61K 51/0402 (2013.01); A61K 51/0406 (2013.01); A61K 51/0446 (2013.01); A61K 51/0453 (2013.01); A61K 51/0455 (2013.01); A61K 51/0491 (2013.01); B01J 19/0093 (2013.01); B01J 2219/00788 (2013.01); B01J 2219/00873 (2013.01); B01J 2219/00891 (2013.01); B01J 2219/00905 (2013.01); B01J 2219/00909 (2013.01);
Abstract

Microfluidic radiopharmaceutical production system and process for synthesizing per run approximately, but not less than, ten (10) unit doses of radiopharmaceutical biomarker for use in positron emission tomography (PET). A radioisotope from an accelerator or other radioisotope generator is introduced into a reaction vessel, along with organic and aqueous reagents, and the mixture heated to synthesize a solution of a pre-selected radiopharmaceutical. The solution is purified by passing through a combination of solid phase extraction purification components, trap and release components, and a filter. The synthesis process reduces waste and allows for production of biomarker radiopharmaceuticals on site and close to the location where the unit dose will be administered to the patient. On-site, as-needed production of radiopharmaceuticals in small doses reduces the time between synthesis of the radiopharmaceutical and administration of that radiopharmaceutical, minimizing loss of active isotopes through decay and allowing production of lesser amounts of radioisotopes overall.


Find Patent Forward Citations

Loading…